Pharmalot's Ed Silverman discusses the results of the National Pharmaceutical Council's recent survey on comparative effectiveness research and why, according to the data, the concept doesn't appear to be a "potent" one.
Get the full story
This story is free
for registered users
Registering provides access to this and other free content.
Register now.Already have an account?
Login Now.